Wipro Limited, today declared a partnership with Transcell Oncologics to transform vaccine safety assessment using artificial intelligence (AI). This alliance combines Transcell’s innovative stem cell technology with the advanced artificial intelligence capabilities of Wipro HOLMES, enabling customers to improve the safety of global vaccine immunization programs.

This alliance will add a new portfolio to Wipro HOLMES life sciences capability, which has impactful offerings that apply AI for drug repurposing and Messenger Ribonucleic Acid (mRNA) based platform for biodefense. The portfolio of solutions jointly developed with Transcell highlights Wipro’s commitment to improve people’s lives through responsible use of AI.

The solution enables the testing of new vaccines by using AI on human stem cells for the required insights on safety and potency. This is the first in a series of next generation solutions that this alliance will offer as viable alternatives to animal based testing, in order to determine the safety and efficacy of drugs, consumer goods including cosmetics.

Applying AI to stem cells will help create a solution capable of predicting the adverse neurovirulent impact caused by vaccination on a vaccine candidate. The adaptable solution developed can be integrated into any existing workflow, including quality control tests in vaccine production, batchwise release and related housekeeping safety evaluation assays.

Harmeet Chauhan, Global Head - Engineering and R&D, Wipro Limited stated, “Enhancing neurovirulence safety assessment through AI, without the need for animal-based testing is a huge step forward. This innovative technology has allowed us to embrace a more humane approach and simultaneously increased the effectiveness of vaccine testing. Our partnership with Transcell Oncologics will bring the best of AI and stem cell technology to users, enabling customers to reduce their go to market timeline and accelerate the safe vaccination program.”

Subhadra Dravida, Founder CEO, Transcell stated, “This exciting alliance merges the biotechnology capabilities of Transcell Oncologics’s Transtoxbio vertical with the advanced AI capabilities of Wipro HOLMES to derive wholistic insights from human surrogate in vitro platforms employed. This breakthrough process will open up new possibilities in the life sciences industry and accelerate innovation that is vital to saving lives.”